Zhang Jing, Zhou Jiao, Tang Xi, Zhou Ling-Yu, Zhai Ling-Ling, Vanessa Minse Evola-Deniz, Yi Jing, Yi Yun-Yun, Lin Jiang, Qian Jun, Deng Zhao-Qun
Department of Laboratory Center, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, 212002, Jiangsu, People's Republic of China.
Department of Hematology, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, 212002, Jiangsu, People's Republic of China.
Oncotarget. 2017 Sep 30;8(54):92536-92544. doi: 10.18632/oncotarget.21440. eCollection 2017 Nov 3.
Chemerin is dysregulation in numerous solid cancers. However, only little is known about the role of chemerin in acute myeloid leukemia (AML). In this study, we aimed to investigate the expression and clinical significance of recently described chemerin in acute myeloid leukemia (AML). The expression of chemerin in 149 patients with de novo AML and 35 normal controls was quantified by Real-time quantitative PCR (RQ-PCR). Chemerin was down-expressed in AML compared with controls (P=0.042). A receiver operating characteristic (ROC) curve revealed that chemerin expression could differentiate patients with AML from control subjects (AUC=0.611, 95% CI: 0.490-0.732; P=0.042) respectively. The cohort of AML patients was divided into two groups according to the cut-off value of 0.0826 (79% sensitivity and 54% specificity, respectively). In addition, the AML patients with low chemerin expression had significantly shorter overall survival (OS) than those with high chemerin expression (P=0.049). Moreover, multivariate survival analysis confirmed that chemerin was an independent prognostic factor for AML patients. In conclusion, downregulation of chemerin might be a useful diagnostic and prognostic factor for AML patients.
在众多实体癌中，chemerin存在失调现象。然而，关于chemerin在急性髓系白血病（AML）中的作用，人们所知甚少。在本研究中，我们旨在探究最近报道的chemerin在急性髓系白血病（AML）中的表达及临床意义。通过实时定量PCR（RQ-PCR）对149例初发AML患者和35例正常对照者中chemerin的表达进行定量分析。与对照组相比，chemerin在AML中表达下调（P = 0.042）。受试者工作特征（ROC）曲线显示，chemerin表达能够分别区分AML患者与对照者（AUC = 0.611，95%CI：0.490 - 0.732；P = 0.042）。根据截断值0.0826将AML患者队列分为两组（敏感性分别为79%和特异性分别为54%）。此外，chemerin低表达的AML患者总生存期（OS）显著短于chemerin高表达的患者（P = 0.049）。而且，多因素生存分析证实chemerin是AML患者的独立预后因素。总之，chemerin下调可能是AML患者有用的诊断和预后因素。
